Mylan recently announced that its shareholders had approved its merger with Pfizer’s Upjohn, to form a new company called Viatris. One asset within Upjohn is Greenstone, a generic manufacturer that focuses on authorized generics. Given the news of the merger, we were interested to better understand the concentration risk on the U.S. generic marketplace by the marriage of Mylan and Greenstone. The good news is that we already have a tool that gives us an idea of who has what market share (using Medicaid data) for every drug. While not a complete assessment of our nation’s generic manufacturer market share, the Medicaid data provides a substantive snapshot of the overall market distribution for the production of each generic drug. Here’s what we found.
Read More
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price decreases this past month, and an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.
Read More
Last week, the FDA dropped the big news that they had given the greenlight for generic manufacturers to officially enter the market to begin competing with Pfizer's blockbuster nerve pain medication, Lyrica. Not only was Lyrica going generic, but a whopping 10 manufacturers were approved to immediately begin releasing copycat versions into the prescription drug supply chain. With all the pricing criticism that Pfizer faced in years past over the drug, we knew that this would be a big moment for those who were unhappy with the brand-version's price. And we knew that with 10 different generic manufacturers, the price would likely drop pretty quickly. So, now that the generic has officially hit pharmacy shelves, we called some pharmacies to see just how low the price had gone, and we were stunned by the numbers.
Read More